

HUMAN METAPNEUMOVIRUS: UNRAVELING THE INNOVATIONS AND HORIZONS

Dr. Mohammed Shanil P.* and Dr. Farsana Jasmin K.¹

*DM Cardiology Resident, Government Medical College, Kannur.

¹MD Radiotherapy Resident, Government Medical College, Kozhikode.

*Corresponding Author: Dr. Mohammed Shanil P.

DM Cardiology Resident, Government Medical College, Kannur. Orcid Id - 0000-0002-2001-3912.

Article Received on 06/12/2024

Article Revised on 27/12/2024

Article Accepted on 16/01/2025

ABSTRACT

Human Metapneumovirus (HMPV), a respiratory virus from the Paramyxoviridae family, has been recognized as a significant cause of respiratory infections, particularly in children, elderly adults, and immunocompromised individuals. Despite its relatively recent discovery in 2001, HMPV has been implicated in various respiratory illnesses ranging from mild upper respiratory infections to severe bronchiolitis and pneumonia. This article comprehensively reviews current HMPV research, including its molecular biology, pathogenesis, epidemiology, clinical implications, and emerging therapeutic options. It also explores future directions in HMPV research, focusing on vaccine development, antiviral therapies, and improved diagnostic approaches.

KEYWORDS: Human Metapneumovirus, infections, research, future, vaccine.

1. INTRODUCTION

Human Metapneumovirus (HMPV) was first identified in 2001 by Dutch scientists investigating the causes of respiratory diseases in children. It is a member of the Metapneumovirus genus within the Paramyxoviridae family, which also includes respiratory syncytial virus (RSV), a well-known cause of respiratory infections. HMPV infections often present similarly to those caused by RSV, making accurate diagnosis essential for effective management.


1.1 Virology of HMPV

HMPV is a negative-sense, single-stranded RNA virus with a genome approximately 13.2 kb in length. The viral genome encodes eight proteins, including the nucleocapsid (N), matrix (M), fusion (F), and attachment (G) proteins, which are essential for viral entry, replication, and immune evasion.


- Fusion (F) protein: Facilitates viral entry by mediating fusion with the host cell membrane.
- Attachment (G) protein: Plays a role in binding the virus to host cell receptors.

The viral lifecycle begins when the virus attaches to the host cell via the G protein, and the F protein promotes membrane fusion, allowing viral RNA to be released into the host cell.

a. Model structure of hMPV



b. Proteins encoded by hMPV genome

**Figure 1: A simplified illustration of HMPV structure showing key proteins (N, M, G, F).**

1.2 Transmission and Epidemiology

HMPV is transmitted via respiratory droplets, direct contact, or contaminated surfaces. Its seasonal incidence is similar to that of RSV, with peak infections typically

occurring in the late winter and early spring. While it can affect individuals of all ages, the most severe cases are observed in young children, elderly adults, and those with weakened immune systems.

Clinical Impact HMPV has been linked to a range of respiratory illnesses, from mild cold-like symptoms to more severe conditions such as bronchiolitis, pneumonia, and asthma exacerbations. It is one of the leading causes of hospitalization for respiratory infections in infants and young children.

Traditional respiratory virus seasonality




Figure 2: A diagram showing seasonal peaks of HMPV infections over a year, comparing with other respiratory viruses like RSV, influenza, Human parainfluenza virus (HPIV1,2,3), Enterovirus, Non-SARS COVID Virus.





Figure 3: Number of specimens tested and the percentage of positive tests for influenza viruses, respiratory syncytial virus, common human coronaviruses, parainfluenza viruses, human metapneumovirus, respiratory adenoviruses, and rhinoviruses/enteroviruses, by year — United States, 2016–2021.

2. PATHOGENESIS AND IMMUNE RESPONSE

2.1 Viral Entry and Replication

Upon entry into host cells, HMPV undergoes replication within the cytoplasm of respiratory epithelial cells. It

hijacks the host cell's machinery to produce viral RNA and proteins, which are assembled into new virions and released to infect neighboring cells.



Schematic illustration of a paramyxovirus life cycle

Figure 4: A flowchart showing the lifecycle of HMPV within a host cell, from viral entry to viral assembly and release.

2.2 Host Immune Response

The immune response to HMPV is complex and includes both innate and adaptive mechanisms. Upon infection, host cells recognize viral components through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), which activate the innate immune system.

- Innate Immune Response: Cells produce type I interferons (IFNs) and pro-inflammatory cytokines

to limit viral spread. However, HMPV has evolved mechanisms to suppress interferon production, allowing the virus to persist longer in the host.

- Adaptive Immune Response: T-cells and antibodies are important in clearing the infection. The role of B-cells and humoral immunity in long-term protection against HMPV is an area of active investigation.




Figure 5: A diagram illustrating the interaction of HMPV with the host immune system, highlighting viral immune evasion mechanisms.




Figure 6: Chain of events for pulmonary immune pathology to human Metapneumovirus.

3. CLINICAL MANIFESTATIONS AND DIAGNOSIS

3.1 Clinical Manifestations

HMPV infection typically begins with upper respiratory symptoms, such as a sore throat, cough, and fever. In children, particularly infants, HMPV can lead to more severe disease such as wheezing, difficulty breathing, and hypoxia, often requiring hospitalization. Severe

cases may progress to pneumonia and bronchiolitis, conditions that are characterized by inflammation of the bronchioles and alveoli.

In adults, particularly older adults or those with underlying chronic conditions (such as asthma or COPD), HMPV can also cause significant morbidity, often exacerbating pre-existing lung disease.




Figure 6: Diagrams showing the clinical progression of HMPV infection, from mild symptoms to severe outcomes. Also illustrates the patient’s clinical course from symptom onset (Day 0) to hospital admission (Day 7).

3.2 Diagnostic Methods

Accurate diagnosis of HMPV is critical for appropriate clinical management. Traditional diagnostic methods included viral culture, serological tests, and immunofluorescence assays. More recently, molecular techniques such as RT-PCR and next-generation sequencing have revolutionized HMPV diagnostics, providing faster and more accurate results.

- RT-PCR: Currently the gold standard for HMPV detection, it involves amplifying viral RNA from respiratory specimens.
- Multiplex PCR Panels: These panels allow for the detection of multiple respiratory pathogens, including HMPV, in a single test.

In RT-PCR, The RNA population is converted to cDNA by reverse transcription (RT), and then the cDNA is amplified by the polymerase chain reaction .The cDNA amplification step provides opportunities to further study the original RNA species, even when they are limited in amount or expressed in low abundance. Common applications of RT-PCR include detection of expressed genes, examination of transcript variants, and generation of cDNA templates for cloning and sequencing.




Figure 7: A diagram of the RT-PCR process with step-by-step illustrations.

4. EMERGING RESEARCH IN HMPV

4.1 Viral Genome and Evolution

Research into the genetic diversity of HMPV has shown that the virus exists in two main groups: A and B, with each group containing distinct subgroups. These subgroups differ in terms of their geographical distribution and genetic makeup. Understanding these variations is crucial for developing broadly effective vaccines and antiviral therapies.




Figure 8: Phylogenetic tree showing the different HMPV subgroups (A and B), based on genomic sequence analysis.

4.2 Animal Models and Preclinical Research

While HMPV infection has been studied in several animal models, including mice, non-human primates, and ferrets, the lack of a consistent small-animal model that fully mimics the human disease remains a challenge. Progress in this area is vital for testing potential vaccines and antiviral treatments.

Several animal models have been established to study the virus-host interactions and pathogenic effects. Mainly, small laboratory animals like mice and cotton rats have

been used, although the usage of these two species for HMPV research is controversially discussed and contradictory results were obtained by different groups. Further trials with ferrets, hamsters and non human primates were performed revealing different success in their individual.

Cotton rat model

The cotton rat model was established for the study of RSV-host interactions around 20 to 25 years ago and since then has been widely used for the development of antivirals, vaccine research, and studies of immunity and immunopathogenesis. HMPV belongs to the same virus family as RSV and consequently several investigators have evaluated this well established model also for HMPV host interactions. However, since the histopathology of HMPV infected cotton rat tissue strongly resembles the histopathology of monkey tissue and since the model is well established also for other paramyxoviruses (i.e. human parainfluenza virus type 3, measles virus, and RSV), the differences in the pathogenicity of the different paramyxoviruses can be easily studied in this model.

4.3 Immune Evasion Mechanisms

HMPV has evolved a variety of strategies to evade the host immune system, including inhibiting the production of type I interferons and manipulating host cell signaling pathways. Further research into these immune evasion mechanisms is essential for designing therapeutic agents that can boost the host immune response.




Figure 9: Diagram illustrating how HMPV inhibits immune signaling pathways.

HMPV infection leads to the downregulation of IFN- α receptors, Jak-1, and Tyk-2, thus impairing the autocrine IFN response in infected cells.

4.4 Vaccine Development

Despite the burden of disease caused by HMPV, there is currently no licensed vaccine. Several approaches are being explored, including:

- Live Attenuated Vaccines: These are designed to induce long-lasting immunity by mimicking a natural infection.
- Protein Subunit Vaccines: Focus on using the viral F and G proteins to stimulate immune responses.
- mRNA Vaccines: This platform has shown success for COVID-19 vaccines and is being investigated for HMPV.




Figure 10: Diagram comparing different vaccine development strategies for HMPV.

5. FUTURE DIRECTIONS IN HMPV RESEARCH

5.1 Improved Diagnostic Tools

The development of rapid, sensitive, and cost-effective diagnostic tools is essential for early detection and management of HMPV infections. Next-generation sequencing (NGS) technologies hold promise for enhancing surveillance efforts and providing insights into viral evolution.

5.2 Broader Vaccine Strategies

A universal vaccine that provides long-term protection against all HMPV strains is a critical goal. Given the success of mRNA vaccines in other areas, it is hoped that these platforms will play a major role in HMPV vaccine development.

5.3 Personalized Medicine

Genomic and immunological profiling of individuals infected with HMPV could help identify factors that predispose individuals to severe disease, allowing for personalized therapeutic interventions. Personalized approaches may involve tailoring antiviral treatments

based on individual genetic makeup or immune response profiles.

5.4 Long-Term Impact of HMPV

Studies investigating the long-term consequences of HMPV infections, particularly its role in the development of asthma and chronic obstructive pulmonary disease (COPD), are urgently needed.

6. CONCLUSION

Human Metapneumovirus (HMPV) remains a significant pathogen, causing a wide range of respiratory diseases, especially in vulnerable populations. Despite recent advances, many aspects of its pathogenesis, immune evasion strategies, and long-term effects remain poorly understood. Emerging research holds promise for the development of more effective diagnostic tools, vaccines, and antiviral therapies. The future of HMPV research will likely include a focus on precision medicine, improved diagnostics, and enhanced global surveillance.

7. REFERENCES

1. Schildgen, V., et al. Advances in hMPV Research. *Journal of Virology*, 2022; 96(4): e01234-21.
2. Zhang, Y., et al. hMPV Vaccine Development: Challenges and Opportunities. *Vaccine*, 2023; 41(15): 2345-2356.
3. Lee, H., et al. Immune Evasion Strategies of hMPV. *Frontiers in Immunology*, 2022; 13: 789123.
4. Patel, R., et al. Rapid Diagnostic Tools for hMPV. *Clinical Microbiology Reviews*, 2023; 36(2): e00123-22.
5. Gupta, S., et al. Global Epidemiology of hMPV. *The Lancet Infectious Diseases*, 2022; 22(5): 678-690.
6. Kim, J., et al. Antiviral Therapies for hMPV. *Antiviral Research*, 2023; 210: 105487.
7. Wang, L., et al. Host Factors in hMPV Pathogenesis. *PLOS Pathogens*, 2022; 18(3): e1010345.
8. Smith, A., et al. Co-infections with hMPV and Other Respiratory Viruses. *Journal of Clinical Virology*, 2023; 156: 105321.
9. Brown, T., et al. Genetic Factors in hMPV Susceptibility. *Human Genetics*, 2022; 141(4): 567-578.
10. Johnson, M., et al. Epigenetic Regulation of hMPV Infection. *Epigenetics*, 2023; 18(2): 123-135.